SkinBioTherapeutics Strengthens Leadership Team with New Appointments

SkinBioTherapeutics plc, a Newcastle-based Life Science HealthTech company, has announced significant changes to its leadership team. Simon Hewitson has been appointed as the new Chief Operating Officer (COO) and has joined the board. Hewitson comes with a wealth of experience in corporate finance, having held CEO, CFO, and director roles over a 25-year career and orchestrated multiple M&A transactions. Emily Bertram has been named the group's Finance Director in a non-board capacity, succeeding Manprit Randhawa. Bertram is returning to SkinBioTherapeutics after previously managing its finance function and brings extensive experience across various industries. These appointments are aligned with the company's active M&A strategy and efforts to drive further growth, a necessity amplified by the recent launch of the Croda Zenakine active ingredient. Current market metrics indicate a share price of 25p and a market cap of £58.19m. Martin Hunt, the chair, praised the expertise that Hewitson and Bertram bring to the company while acknowledging Randhawa's contributions during his tenure.